Brought to you by 
Agouron licenses Japan Energy's HIV protease inhibitor
29 Mar 2011
Executive Summary
Agouron Pharmaceuticals has licensed development and marketing rights in North America, Europe, and several other territories to diversified Japan Energy Corp.'s HIV protease inhibitor, JE-2147. JEC will retain Japanese, Korean, and Taiwanese rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Agouron licenses Japan Energy's HIV protease inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice